Quantum Biopharma Ltd.QNTM
Price (close)
$4.00
Market cap
—
P/E
—
Revenue (FY)
—
Net income
—
Dividend yield
—
1-year total return
-76.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What Quantum Biopharma Ltd. does.
dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory
of development. Through Lucid, the Company is currently focused on the R&D of its lead compound, Lucid-MS (formerly Lucid-21-302).
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$31.8M | $0 | $0 | — | — | — |
| Free cash flow | -$19.1M | -$20.7M | -$28.4M | -$10.8M | -$6.9M | — |
More on QNTM.
- Quantum Biopharma Ltd. summary
- Quantum Biopharma Ltd. financial statements
- Quantum Biopharma Ltd. key metrics
- Quantum Biopharma Ltd. health scores and style box
- Quantum Biopharma Ltd. earnings
- Quantum Biopharma Ltd. dividends
- Quantum Biopharma Ltd. valuation
- Quantum Biopharma Ltd. ownership and insiders
- Quantum Biopharma Ltd. peers
Figures from Quantum Biopharma Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.